GlobeNewsWire
18 Jun 2026, 01:21 UTC · 2h ago
Legend Biotech Corporation Announces Pricing of Public Offering
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
18 Jun 2026, 01:21 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Legend Biotech is conducting a public offering of 7,700,000 American Depositary Shares at $29.35 per ADS. — Equity offerings typically create immediate downward pressure on share prices due to dilution of existing shareholders.
-0.40The company expects to raise approximately $226 million in gross proceeds from the offering. — Increased cash reserves provide a capital cushion for R&D and commercial operations, which is generally positive for biotech longevity.
+0.20Underwriters have been granted a 30-day option to purchase up to an additional 1,155,000 ADSs. — The potential for additional shares to enter the market increases the total possible dilution.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
The announcement of a public offering typically leads to share dilution for existing investors.
The company is mentioned as a collaborator for CARVYKTI, but the news focuses on Legend Biotech's financing.
[mutual] Legend Biotech develops and markets CARVYKTI with collaborator Johnson & Johnson.
[a_to_b] Citigroup is serving as a joint book-running manager for Legend Biotech's public offering.
[a_to_b] Deutsche Bank is serving as a joint book-running manager for Legend Biotech's public offering.
[a_to_b] Morgan Stanley is serving as a joint book-running manager for Legend Biotech's public offering.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
40m ago
